Author, as appears in the article.: Averna, Maurizio; Banach, Maciej; Bruckert, Eric; Drexel, Heinz; Farnier, Michel; Gaita, Dan; Magni, Paolo; Maerz, Winfried; Masana, Luis; Mello e Silva, Alberto; Reiner, Zeljko; Ros, Emilio; Vrablik, Michal; Zambon, Alberto; Zamorano, Jose L.; Stock, Jane K.; Tokgozoglu, Lale S.; Catapano, Alberico L.;
Department: Medicina i Cirurgia
URV's Author/s: Masana Marín, Luis
Keywords: Triglycerides Triacylglycerol Statin (protein) Risk reduction Risk benefit analysis Reduction (chemistry) Recurrent disease Proteinase inhibitor Proprotein convertase 9 Priority journal Practice guideline Pcsk9 protein, human Pcsk9 inhibitor evolocumab Of-function mutations Nutraceutical Note Non insulin dependent diabetes mellitus Monoclonal antibody Medical society Male Low density lipoprotein cholesterol level Low density lipoprotein cholesterol Lipid storage Lipid goals Ldl-c Ldl cholesterol Inflammation Inclisiran Icosapentaenoic acid ethyl ester Hypocholesterolemic agent Hypertriglyceridemia Hydroxymethylglutaryl-coa reductase inhibitors Hydroxymethylglutaryl coenzyme a reductase inhibitor Humans Human High-risk High risk patient High density lipoprotein cholesterol level High density lipoprotein cholesterol Heterozygous familial hypercholesterolemia Health care quality Goal attainment Fibric acid derivative Fenofibrate therapy Fenofibrate Female Familial hypercholesterolemia Ezetimibe Evidence based practice Eas dyslipidaemia guidelines Drug efficacy Dietary portfolio Diabetes mellitus, type 2 Density-lipoprotein cholesterol Coronary artery atherosclerosis Combination treatment Combination drug therapy Clinical trial (topic) Cholesterol, ldl Cardiovascular risk Cardiovascular effect Atherosclerosis Atherogenic index Anticholesteremic agents Adult Acute-coronary-syndrome Acid 2019 esc/eas dyslipidaemia guidelines 2019 esc
Abstract: Background and aims: This European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in highrisk and very-high-risk patients.
Methods: Evidence-based review.
Results: Statin-ezetimibe combination treatment is the first choice for managing elevated LDL-C and should be given upfront in very-high-risk patients with high LDL-C unlikely to reach goal with a statin, and in primary prevention familial hypercholesterolaemia patients. A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor may be added if LDL-C levels remain high. In high and very-high-risk patients with mild to moderately elevated TG levels (>2.3 and < 5.6 mmol/L [>200 and < 500 mg/dL) on a statin, treatment with either a fibrate or high-dose omega-3 fatty acids (icosapent ethyl) may be considered, weighing the benefit versus risks. Combination with fenofibrate may be considered for both macro- and microvascular benefits in patients with type 2 diabetes mellitus.
Conclusions: This guidance aims to improve real-world use of guideline-recommended combination lipid modifying treatment.
Thematic Areas: Saúde coletiva Psicología Peripheral vascular disease Odontología Nutrição Medicina iii Medicina ii Medicina i Interdisciplinar General medicine Farmacia Engenharias ii Enfermagem Educação física Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciência de alimentos Ciência da computação Cardiology and cardiovascular medicine Cardiac & cardiovascular systems Biotecnología Antropologia / arqueologia
licence for use: https://creativecommons.org/licenses/by/3.0/es/
Author's mail: luis.masana@urv.cat
Author identifier: 0000-0002-0789-4954
Record's date: 2024-07-27
Papper version: info:eu-repo/semantics/acceptedVersion
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Papper original source: Atherosclerosis. 325 99-109
APA: Averna, Maurizio; Banach, Maciej; Bruckert, Eric; Drexel, Heinz; Farnier, Michel; Gaita, Dan; Magni, Paolo; Maerz, Winfried; Masana, Luis; Mello e Sil (2021). Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis, 325(), 99-109. DOI: 10.1016/j.atherosclerosis.2021.03.039
Entity: Universitat Rovira i Virgili
Journal publication year: 2021
Publication Type: Journal Publications
Repositori URV